@article{8fc9bd652e7545f79e69dba12114f543,
title = "The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials",
abstract = "The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell–mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.",
keywords = "classification systems: Banff classification, kidney transplantation/nephrology, molecular biology, pathology/histopathology, rejection, translational research/science",
author = "M. Haas and A. Loupy and C. Lefaucheur and C. Roufosse and D. Glotz and D. Seron and Nankivell, {B. J.} and Halloran, {P. F.} and Colvin, {R. B.} and Enver Akalin and N. Alachkar and S. Bagnasco and Y. Bouatou and Becker, {J. U.} and Cornell, {L. D.} and {van Huyen}, {J. P.Duong} and Gibson, {I. W.} and Kraus, {Edward S.} and Mannon, {R. B.} and M. Naesens and V. Nickeleit and P. Nickerson and Segev, {D. L.} and Singh, {H. K.} and M. Stegall and P. Randhawa and L. Racusen and K. Solez and M. Mengel",
note = "Funding Information: We would like to acknowledge the instrumental support from the Roche Organ Transplantation Research Foundation Grant 608390948 awarded to Dr Kim Solez, which allowed establishment of the Banff Foundation for Allograft Pathology. The joint 2017 Banff and Catalan Transplant Society meeting acknowledges the receipt of sponsorship from Astellas, Chiesi, Novartis, One Lambda, Shire, Renal Pathology Society, American Society of Transplantation, Wiley, and Qiagen. Funding Information: Enver Akalin, Nada Alachkar, Serena Bagnasco, Jan Ulrich Becker, Robert Colvin, Yassine Bouatou, Lynn Cornell, Jean Paul Duong van Huyen, Ian Gibson, Denis Glotz, Ed Kraus, Roslyn Mannon, Maarten Naesens, Brian Nankivell, Volker Nickeleit, Lorraine. Racusen, Parmjeet Randhawa, Candice Roufosse, Dorry Segev, Daniel Seron, Harsharan Singh, Kim Solez, Mark Stegall had nothing to disclose. Carmen Lefaucheur and Alexandre Loupy received honoraria from Astellas and CSL Behring. They also received travel grants from ThermoFischer and Chiesi. Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma – Treatment of Acute Antibody-Mediated Rejection and AstraZeneca – Treatment of Proliferative Lupus Nephritis Philip F Halloran has shares in Transcriptome Sciences Inc (TYI), a University of Alberta spin-off company dedicated to developing molecular diagnostic solutions. Michael Mengel, research funding and honorarium from Shire Inc. Peter Nickerson, Consultant for Astellas Pharma and Vitaeris Inc. Funding Information: We would like to acknowledge the instrumental support from the Roche Organ Transplantation Research Foundation Grant 608390948 awarded to Dr Kim Solez, which allowed establishment of the Banff Foundation for Allograft Pathology. The joint 2017 Banff and Catalan Transplant Society meeting acknowledges the receipt of sponsorship from Astellas, Chiesi, Novartis, One Lambda, Shire, Renal Pathology Society, American Society of Transplantation, Wiley, and Qiagen. Enver Akalin, Nada Alachkar, Serena Bagnasco, Jan Ulrich Becker, Robert Colvin, Yassine Bouatou, Lynn Cornell, Jean Paul Duong van Huyen, Ian Gibson, Denis Glotz, Ed Kraus, Roslyn Mannon, Maarten Naesens, Brian Nankivell, Volker Nickeleit, Lorraine. Racusen, Parmjeet Randhawa, Candice Roufosse, Dorry Segev, Daniel Seron, Harsharan Singh, Kim Solez, Mark Stegall had nothing to disclose. Carmen Lefaucheur and Alexandre Loupy received honoraria from Astellas and CSL Behring. They also received travel grants from ThermoFischer and Chiesi. Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma ? Treatment of Acute Antibody-Mediated Rejection and AstraZeneca ? Treatment of Proliferative Lupus Nephritis Philip F Halloran has shares in Transcriptome Sciences Inc (TYI), a University of Alberta spin-off company dedicated to developing molecular diagnostic solutions. Michael Mengel, research funding and honorarium from Shire Inc. Peter Nickerson, Consultant for Astellas Pharma and Vitaeris Inc. Publisher Copyright: {\textcopyright} 2017 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons",
year = "2018",
month = feb,
doi = "10.1111/ajt.14625",
language = "English (US)",
volume = "18",
pages = "293--307",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "2",
}